Business
Dyadic Reports 2021 Year End Results and Recent Company Progress
New research, license and collaboration agreement with Janssen for the development and manufacture of therapeutic proteinsReceived NIIMBL coronavirus grant of
About this update from Dyadic International, Inc.
[{"type":"text","content":"New research, license and collaboration agreement with Janssen for the development and manufacture of therapeutic proteinsReceived NIIMBL coronavirus grant of $690,000 under the White House’s American Rescue PlanNew license agreement with Phibro Animal Health to develop and commercialize certain animal health vaccinesExpecting to advance proprietary DYAI-100 COVID-19 vaccine candidate towards first-in-human clinical trialExecutive leadership team enhanced with the appointment of Joseph Hazelton as Chief Business OfficerManuscripts published in three highly regarded vaccine scientific journalsPeer reviewed manuscript demonstrating safety and persistence of C1-cell produced DYAI-100 vaccine candidate is awaiting publication in “Toxicologic Pathology”Research and development revenue increased 50.0% to $2.4 million in 2021Cash and investment grade securities of $20.4 million at year-end 2021 JUPITER, Fla., March 29, 2022 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further improving, applying and deploying its proprietary C1-cell protein production platform to accelerate development, lower production costs and improve the performance of biologic vaccines and therapeutics today announced its financial results for year end 2021 and highlighted recent Company progress. Mark Emalfarb, Dyadic's President and Chief Executive Officer, said, \"The C1-cell protein production platform has the potential to address the ongoing need to affordably and rapidly produce vast amounts of vaccines in response to emerging infectious disease threats. We are very encouraged by the growing industry interest and broad commercial possibilities of leveraging our C1-cell protein production platform and our other technologies for use in manufacturing a growing number of vaccines, antibodies, therapeutic proteins and other biologic products. Dyadic continues to develop both strategically and operationally, enhancing our business development and scientific capabilities enabling us to focus our 2022 operating plan on human and animal health, while leveraging other biomolecule market opportunities. As such, we believe that Dyadic has the potential to reshape the current landscape of biomanufacturing. In the meantime, we are pivoting from successfully demonstr...